{"id":"https://openalex.org/W2223123737","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7528","title":"Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).","display_name":"Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2223123737","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7528","mag":"2223123737"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.7528","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7528","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7528","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108569702","display_name":"G. R. Blumenschein","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. R. Blumenschein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006496749","display_name":"Fairooz F. Kabbinavar","orcid":"https://orcid.org/0009-0003-2552-4935","observed_orcids":["https://orcid.org/0009-0003-2552-4935"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. F. Kabbinavar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066698956","display_name":"Hari Menon","orcid":"https://orcid.org/0000-0001-5684-1405","observed_orcids":["https://orcid.org/0000-0001-5684-1405"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Menon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066717752","display_name":"Tony S.K. Mok","orcid":"https://orcid.org/0000-0002-8251-0551","observed_orcids":["https://orcid.org/0000-0002-8251-0551"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Mok","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111152505","display_name":"J. Stephenson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Stephenson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108230454","display_name":"Joseph T. Beck","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. T. Beck","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113679812","display_name":"Kuntegowdanahalli Chinnagiriyappa Lakshmaiah","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Lakshmaiah","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112279553","display_name":"Karolyn Kracht","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Kracht","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113639016","display_name":"Robert S. Sikorski","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. S. Sikorski","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5072563567","display_name":"Lee Steven Schwartzberg","orcid":"https://orcid.org/0000-0002-7433-3428","observed_orcids":["https://orcid.org/0000-0002-7433-3428"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. S. Schwartzberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"7528","last_page":"7528"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9692000150680542,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9692000150680542,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.023099999874830246,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/motesanib","display_name":"motesanib","score":0.984000027179718},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9539999961853027},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":1.0},{"id":"https://openalex.org/keywords/non-squamous-non-small-cell-lung-cancer","display_name":"non-squamous non-small cell lung cancer","score":0.906000018119812},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.7749999761581421},{"id":"https://openalex.org/keywords/vegf-receptor-antagonist","display_name":"VEGF receptor antagonist","score":0.7160000205039978},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8519999980926514},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9139999747276306},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9950000047683716},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9369999766349792},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8029999732971191},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.38600000739097595},{"id":"https://openalex.org/keywords/pleural-effusion","display_name":"pleural effusion","score":0.5659999847412109}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9289047718048096},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8276082277297974},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6947405338287354},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.60759037733078},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5602089166641235},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5215180516242981},{"id":"https://openalex.org/C2779634585","wikidata":"https://www.wikidata.org/wiki/Q1334541","display_name":"Pleural effusion","level":2,"score":0.4740324318408966},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4716479182243347},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.46900367736816406},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4500581920146942},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.43889251351356506},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.41569989919662476},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.40576764941215515},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3697739243507385},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.317382276058197},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.24926573038101196},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.7528","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.7528","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.7528","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2157099922","https://openalex.org/W2170024262","https://openalex.org/W2240346141","https://openalex.org/W2755166669","https://openalex.org/W2516096855","https://openalex.org/W2051584624","https://openalex.org/W2135663624","https://openalex.org/W2122569906","https://openalex.org/W3000096364","https://openalex.org/W2963756957"],"abstract_inverted_index":{"7528":[0],"Background:":[1],"Motesanib":[2,347],"is":[3],"a":[4],"small":[5],"molecule":[6],"antagonist":[7],"of":[8,20,31,85,98,142,172,185,216,268,309,334,363],"VEGF":[9],"(1,":[10],"2,":[11],"and":[12,15,38,64,170,238,282,300,327],"3),":[13],"PDGF,":[14],"Kit":[16],"receptors.":[17],"The":[18,150,311,331,358],"objective":[19,27],"this":[21],"study":[22,362],"was":[23,153,208,225,248,341],"to":[24,72,343],"estimate":[25],"the":[26,355],"response":[28],"rates":[29],"(ORR)":[30],"motesanib":[32,93,335,364],"(two":[33],"dosing":[34,349],"cohorts)":[35],"+":[36,40,77,131,339,345,368],"P/C":[37,41,130,340,369],"bevacizumab":[39,132,344],"in":[42,205,221,229,235,242,246,252,258,264,293,298,307,370],"patients":[43],"(pts)":[44],"with":[45,49,54,194,210],"NSCLC.":[46,372],"Methods:":[47],"Adults":[48],"confirmed":[50],"unresectable,":[51],"stage":[52,60],"IIIB":[53],"pericardial":[55],"or":[56,59,67,111,127,148,376,380],"pleural":[57],"effusion":[58],"IV/recurrent":[61],"nonsquamous":[62,371],"NSCLC":[63,305],"ECOG":[65],"0":[66],"1":[68,84,97,100,141,183],"were":[69,318],"randomized":[70],"(1:1:1)":[71],"receive":[73],"paclitaxel":[74],"(200":[75],"mg/m2)":[76],"carboplatin":[78],"(AUC":[79],"6":[80],"mg/mL/min)":[81],"on":[82,139],"day":[83,96,140],"each":[86,143],"3-week":[87],"cycle":[88,99,144],"(6":[89],"cycles":[90],"max)":[91],"plus":[92],"orally":[94],"from":[95],"at":[101,181,197],"either":[102],"(Arm":[103,112,128],"A)":[104],"125":[105,336,365],"mg":[106,115,337,366],"once":[107,135],"daily":[108,117],"(QD)":[109],"continuously":[110],"B)":[113],"75":[114],"twice":[116],"(BID)":[118],"for":[119],"5":[120,302],"days":[121],"followed":[122],"by":[123,157],"2":[124],"treatment-free":[125],"days;":[126],"C)":[129],"15":[133],"mg/kg":[134],"every":[136],"3":[137,290,316],"weeks":[138],"until":[145],"disease":[146,196],"progression":[147],"intolerability.":[149],"primary":[151],"endpoint":[152],"ORR":[154,204],"per":[155],"RECIST":[156],"independent":[158],"central":[159],"review.":[160],"Secondary":[161],"endpoints":[162],"included":[163,272],"progression-free":[164],"survival":[165,168],"(PFS),":[166],"overall":[167],"(OS),":[169],"incidence":[171],"treatment-emergent":[173],"adverse":[174],"events":[175,276],"(AEs).":[176],"Results:":[177],"181":[178],"pts":[179,193],"received":[180],"least":[182],"dose":[184],"treatment":[186],"(Arms":[187,199,320],"A/B/C,":[188,200,288,321],"n":[189,201],"=":[190,202],"59/62/60).":[191],"In":[192,286],"measurable":[195],"baseline":[198],"57/60/62)":[203],"Arms":[206,287],"A/B/C":[207],"30/23/37%,":[209],"no":[211],"complete":[212],"responses.":[213],"At":[214],"time":[215],"data":[217,359],"cut-off,":[218],"median":[219],"PFS":[220],"months":[222,247],"(95%":[223],"CI)":[224],"8.4":[226],"(6.1,":[227],"10.1)":[228],"Arm":[230,236,243,253,259,265],"A,":[231,254],"6.2":[232],"(4.7,":[233],"6.3)":[234],"B,":[237,260],"9.0":[239],"(7.4,":[240],"11.0)":[241],"C.":[244,266],"OS":[245],"15.2":[249,261],"(8.5,":[250],"20.2)":[251],"13.9":[255],"(8.6,":[256],"18.5)":[257],"(10.2,":[262],"18.2)":[263],"AEs":[267,291,297,303,317],"interest":[269],"(all":[270],"grades)":[271],"cholecystitis":[273],"(5/8/0%),":[274],"hemorrhagic":[275],"(22/24/18%),":[277],"deep":[278],"vein":[279],"thrombosis":[280],"(3/0/2%),":[281],"pulmonary":[283],"embolism":[284],"(3/2/3%).":[285],"grade":[289,295,301,314],"occurred":[292],"46/58/50%,":[294],"4":[296],"10/3/5%,":[299],"(excluding":[304],"progression)":[306],"7/16/7%":[308],"pts.":[310],"most":[312],"common":[313],"\u2265":[315],"diarrhea":[319],"19/11/3%),":[322],"dehydration":[323],"(17/11/3%),":[324],"pneumonia":[325],"(7/10/2%)":[326],"neutropenia":[328],"(7/8/13%).":[329],"Conclusions:":[330],"estimated":[332],"efficacy":[333,353],"QD":[338,367],"similar":[342],"P/C.":[346],"BID":[348],"had":[350],"relatively":[351],"lower":[352],"than":[354],"other":[356],"arms.":[357],"support":[360],"further":[361],"Author":[373],"Disclosure":[374],"Employment":[375],"Leadership":[377],"Position":[378],"Consultant":[379],"Advisory":[381],"Role":[382],"Stock":[383],"Ownership":[384],"Honoraria":[385],"Research":[386],"Funding":[387],"Expert":[388],"Testimony":[389],"Other":[390],"Remuneration":[391],"Amgen":[392,399,405],"Amgen,":[393,400],"AstraZeneca,":[394,401],"Eisai,":[395],"Lilly,":[396,402],"Pfizer,":[397,403],"Roche":[398,404]},"counts_by_year":[{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}